Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Systems Genetics of Hepatic Metabolome Reveals Octopamine as a Target for Non-Alcoholic Fatty Liver Disease Treatment.

Brial F, Le Lay A, Hedjazi L, Tsang T, Fearnside JF, Otto GW, Alzaid F, Wilder SP, Venteclef N, Cazier JB, Nicholson JK, Day C, Burt AD, Gut IG, Lathrop M, Dumas ME, Gauguier D.

Sci Rep. 2019 Mar 6;9(1):3656. doi: 10.1038/s41598-019-40153-0.

2.

Cancer-associated fibroblasts in gastrointestinal cancer.

Kobayashi H, Enomoto A, Woods SL, Burt AD, Takahashi M, Worthley DL.

Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295. doi: 10.1038/s41575-019-0115-0. Review.

PMID:
30778141
3.

The degree of hepatic steatosis associates with impaired cardiac and autonomic function.

Houghton D, Zalewski P, Hallsworth K, Cassidy S, Thoma C, Avery L, Slomko J, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, Masson S, McPherson S, Anstee QM, Newton JL, Trenell MI.

J Hepatol. 2019 Jun;70(6):1203-1213. doi: 10.1016/j.jhep.2019.01.035. Epub 2019 Feb 13.

4.

Effect of time of day and specialty on polyp detection rates in Australia.

Zorron Cheng Tao Pu L, Lu K, Ovenden A, Rana K, Singh G, Krishnamurthi S, Edwards S, Wilson B, Nakamura M, Yamamura T, Ruszkiewicz A, Hirooka Y, Burt AD, Singh R.

J Gastroenterol Hepatol. 2019 May;34(5):899-906. doi: 10.1111/jgh.14566. Epub 2019 Jan 8.

PMID:
30552716
5.

A further change of the guard.

Burt AD.

Histopathology. 2018 Dec;73(6):876-877. doi: 10.1111/his.13774. No abstract available.

PMID:
30460741
6.

Author Correction: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M.

Nature. 2018 Sep;561(7721):E1. doi: 10.1038/s41586-018-0304-y.

PMID:
29973714
7.

Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW.

Histopathology. 2018 Sep;73(3):369-385. doi: 10.1111/his.13520. Epub 2018 May 30. Review.

PMID:
29573451
8.

Erratum: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M.

Nature. 2017 Dec 21;552(7685):430. doi: 10.1038/nature25028. Epub 2017 Nov 22.

PMID:
29168501
9.

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M.

Nature. 2017 Nov 16;551(7680):340-345. doi: 10.1038/nature24302. Epub 2017 Nov 8. Erratum in: Nature. 2017 Nov 22;:. Erratum in: Nature. 2018 Sep;561(7721):E1.

10.

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.

McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP.

PLoS One. 2017 Apr 18;12(4):e0175717. doi: 10.1371/journal.pone.0175717. eCollection 2017.

11.

Annual review issue: surgical pathology of 21st century medicine.

Burt AD.

Histopathology. 2017 Jan;70(1):3. doi: 10.1111/his.13107. No abstract available.

PMID:
27960242
12.

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.

Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, Tiniakos D, Hollingsworth KG, Taylor R, Day CP, McPherson S, Anstee QM, Trenell MI.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):96-102.e3. doi: 10.1016/j.cgh.2016.07.031. Epub 2016 Aug 10.

13.

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.

Alhasan SF, Haugk B, Ogle LF, Beale GS, Long A, Burt AD, Tiniakos D, Televantou D, Coxon F, Newell DR, Charnley R, Reeves HL.

Br J Cancer. 2016 Sep 27;115(7):797-804. doi: 10.1038/bjc.2016.264. Epub 2016 Aug 25.

14.

A prospective observational study of the effect of critical illness on ultrastructural and microscopic morphology of duodenal mucosa.

Liew VY, Chapman MJ, Nguyen NQ, Cousins CE, Plummer MP, Chapple LA, Abdelhamid YA, Manton ND, Swalling A, Sutton-Smith P, Burt AD, Deane AM.

Crit Care Resusc. 2016 Jun;18(2):102-8.

PMID:
27242108
15.
16.

Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification.

Burt AD, Lackner C, Tiniakos DG.

Semin Liver Dis. 2015 Aug;35(3):207-20. doi: 10.1055/s-0035-1562942. Epub 2015 Sep 17. Review.

PMID:
26378639
17.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.

Bedossa P, Burt AD, Brunt E, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2015 Apr;46(4):635-6. doi: 10.1016/j.humpath.2014.10.030. Epub 2014 Dec 31. No abstract available.

PMID:
25732109
18.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL.

Clin Cancer Res. 2015 Feb 15;21(4):925-33. doi: 10.1158/1078-0432.CCR-14-0842. Epub 2014 Dec 5.

19.

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM.

J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1.

20.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM.

Nat Commun. 2014 Jun 30;5:4309. doi: 10.1038/ncomms5309.

21.

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM.

J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6.

PMID:
24607626
22.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category.

Bedossa P, Burt AD, Brunt EM, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2014 Mar;45(3):658-60. doi: 10.1016/j.humpath.2013.09.020. Epub 2013 Nov 21. No abstract available.

PMID:
24529331
23.

Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

McPherson S, Henderson E, Burt AD, Day CP, Anstee QM.

J Hepatol. 2014 May;60(5):1055-62. doi: 10.1016/j.jhep.2014.01.010. Epub 2014 Jan 18.

PMID:
24445215
24.

Pathology of the liver sinusoids.

Brunt EM, Gouw AS, Hubscher SG, Tiniakos DG, Bedossa P, Burt AD, Callea F, Clouston AD, Dienes HP, Goodman ZD, Roberts EA, Roskams T, Terracciano L, Torbenson MS, Wanless IR.

Histopathology. 2014 Jun;64(7):907-20. doi: 10.1111/his.12364. Epub 2014 Mar 8. Review.

PMID:
24393125
25.

Identification of a neuronal transcription factor network involved in medulloblastoma development.

Lastowska M, Al-Afghani H, Al-Balool HH, Sheth H, Mercer E, Coxhead JM, Redfern CP, Peters H, Burt AD, Santibanez-Koref M, Bacon CM, Chesler L, Rust AG, Adams DJ, Williamson D, Clifford SC, Jackson MS.

Acta Neuropathol Commun. 2013 Jul 11;1:35. doi: 10.1186/2051-5960-1-35.

26.

Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease.

Masson S, Emmerson I, Henderson E, Fletcher EH, Burt AD, Day CP, Stewart SF.

Liver Int. 2014 Feb;34(2):235-42. doi: 10.1111/liv.12242. Epub 2013 Jul 8.

PMID:
23834275
27.

Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.

Elsharkawy AM, Schwab U, McCarron B, Burt AD, Daly AK, Hudson M, Masson S.

J Clin Virol. 2013 Sep;58(1):331-3. doi: 10.1016/j.jcv.2013.05.003. Epub 2013 Jun 12.

PMID:
23763943
28.

Development of a robust protocol for gene expression analysis using formalin-fixed, paraffin-embedded liver transplant biopsy specimens.

Thompson E, Burt AD, Barker CE, Kirby JA, Brain JG.

J Clin Pathol. 2013 Sep;66(9):815-8. doi: 10.1136/jclinpath-2013-201548. Epub 2013 Jun 11.

29.

Biliary epithelial senescence and plasticity in acute cellular rejection.

Brain JG, Robertson H, Thompson E, Humphreys EH, Gardner A, Booth TA, Jones DE, Afford SC, von Zglinicki T, Burt AD, Kirby JA.

Am J Transplant. 2013 Jul;13(7):1688-702. doi: 10.1111/ajt.12271. Epub 2013 Jun 10.

30.

Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.

Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA, Mann DA.

J Hepatol. 2013 Aug;59(2):318-26. doi: 10.1016/j.jhep.2013.04.014. Epub 2013 Apr 23.

31.

White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers.

Hardy T, Wells C, Kendrick S, Hudson M, Day CP, Burt AD, Masson S, Stewart SF.

BMC Gastroenterol. 2013 Mar 26;13(1):55. doi: 10.1186/1471-230X-13-55.

32.

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

McPherson S, Anstee QM, Henderson E, Day CP, Burt AD.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8. doi: 10.1097/MEG.0b013e32835d72cf.

PMID:
23325287
33.

Quality really matters: the need to improve specimen quality in biomedical research.

Simeon-Dubach D, Burt AD, Hall PA.

Histopathology. 2012 Dec;61(6):1003-5. doi: 10.1111/his.12060. No abstract available.

PMID:
23190088
34.

Quality really matters: the need to improve specimen quality in biomedical research.

Simeon-Dubach D, Burt AD, Hall PA.

J Pathol. 2012 Dec;228(4):431-3. doi: 10.1002/path.4117.

PMID:
23023660
35.

Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response.

Moles A, Sanchez AM, Banks PS, Murphy LB, Luli S, Borthwick L, Fisher A, O'Reilly S, van Laar JM, White SA, Perkins ND, Burt AD, Mann DA, Oakley F.

Hepatology. 2013 Feb;57(2):817-28. doi: 10.1002/hep.26068. Epub 2013 Jan 8.

36.

Multigenerational epigenetic adaptation of the hepatic wound-healing response.

Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, Oakley F, Burt AD, Wilson CL, Anstee QM, Barter MJ, Masson S, Elsharkawy AM, Mann DA, Mann J.

Nat Med. 2012 Sep;18(9):1369-77. Erratum in: Nat Med. 2012 Oct;18(10):1592.

37.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2013 Jan;57(1):103-11. doi: 10.1002/hep.26030.

PMID:
22930399
38.

Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis.

Robinson SM, Wilson CH, Burt AD, Manas DM, White SA.

Ann Surg Oncol. 2012 Dec;19(13):4287-99. doi: 10.1245/s10434-012-2438-8. Epub 2012 Jul 6. Review.

39.

Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation.

Perugorria MJ, Wilson CL, Zeybel M, Walsh M, Amin S, Robinson S, White SA, Burt AD, Oakley F, Tsukamoto H, Mann DA, Mann J.

Hepatology. 2012 Sep;56(3):1129-39. doi: 10.1002/hep.25754.

40.

Primary hepatocellular carcinoma of the pancreas: a case report and review of the heterogeneous group of pancreatic hepatoid carcinomas.

Kelly PJ, Spence R, Dasari BV, Burt AD, Taylor M, Loughrey MB.

Histopathology. 2012 May;60(6):1012-5. doi: 10.1111/j.1365-2559.2011.04129.x. Epub 2012 Feb 9. Review. No abstract available.

PMID:
22320681
41.

Cholestasis secondary to anabolic steroid use in young men.

Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT, Hudson M.

BMJ. 2012 Feb 2;344:e468. doi: 10.1136/bmj.e468. No abstract available.

PMID:
22302781
42.

Changing of the guard.

Burt AD.

Histopathology. 2012 Jan;60(2):233-5. doi: 10.1111/j.1365-2559.2011.04132.x. No abstract available.

PMID:
22211282
43.

Stimulating healthy tissue regeneration by targeting the 5-HT₂B receptor in chronic liver disease.

Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, Ellis E, Lakey AF, Burt AD, Douglass A, Wright MC, White SA, Jaffré F, Maroteaux L, Mann DA.

Nat Med. 2011 Nov 27;17(12):1668-73. doi: 10.1038/nm.2490.

44.

Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.

Bechmann LP, Gastaldelli A, Vetter D, Patman GL, Pascoe L, Hannivoort RA, Lee UE, Fiel I, Muñoz U, Ciociaro D, Lee YM, Buzzigoli E, Miele L, Hui KY, Bugianesi E, Burt AD, Day CP, Mari A, Agius L, Walker M, Friedman SL, Reeves HL.

Hepatology. 2012 Apr;55(4):1083-93. doi: 10.1002/hep.24793. Epub 2012 Mar 1.

45.

Lymph node metastasis in early esophageal adenocarcinoma.

Griffin SM, Burt AD, Jennings NA.

Ann Surg. 2011 Nov;254(5):731-6; discussion 736-7. doi: 10.1097/SLA.0b013e318236048b.

PMID:
21997815
46.

Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus.

van der Laan LJ, Hudson M, McPherson S, Zondervan PE, Thomas RC, Kwekkeboom J, Lindsay AS, Burt AD, Kazemier G, Tilanus HW, Bassendine MF, Metselaar HJ.

Transplant Proc. 2010 Dec;42(10):4573-7. doi: 10.1016/j.transproceed.2010.10.013.

PMID:
21168740
47.

Mitochondrial DNA does not contribute to the heritability of non-alcoholic fatty liver disease.

de Alwis N, Aithal G, Bugianesi E, Leathart J, Hudson G, Pyle A, Mowbray C, Henderson E, Burt AD, Chinnery PF, Day CP.

Mitochondrion. 2011 Jan;11(1):234-5. doi: 10.1016/j.mito.2010.09.009. Epub 2010 Oct 1. No abstract available.

PMID:
20888438
48.

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP.

Gut. 2010 Sep;59(9):1265-9. doi: 10.1136/gut.2010.216077.

PMID:
20801772
49.

Disrupted pancreatic exocrine differentiation and malabsorption in response to chronic elevated systemic glucocorticoid.

Wallace K, Flecknell PA, Burt AD, Wright MC.

Am J Pathol. 2010 Sep;177(3):1225-32. doi: 10.2353/ajpath.2010.100107. Epub 2010 Jul 22.

50.

Abrikosoff's Tumor and the Hepatobiliary System: A Curiosa Revisited.

Brain JG, Burt AD.

Gastroenterol Hepatol (N Y). 2010 May;6(5):337-8. No abstract available.

Supplemental Content

Support Center